TScan Gets FDA Clearance of Investigational New Drug Application for Cancer Treatment

By Chris Wack

TScan Therapeutics said Tuesday that the U.S. Food and Drug Administration has cleared its investigational new drug application for TSC-203-A0201, a TCR-T targeting preferentially expressed antigen in melanoma.

The clinical-stage biopharmaceutical company said TSC-203-A0201 is the fourth TCR-T cleared for clinical development in the company's solid tumor program.

TScan said it is on-track to treat the first patient with a TScan TCR-T and report preliminary data by the end of 2023.

TScan shares were up 8% to $2.37 in premarket trading.

Write to Chris Wack at [e-mail]

(END) Dow Jones Newswires

08-29-23 0747ET